Ternary Therapeutics

Ternary Therapeutics is a preclinical-stage biotechnology company developing an AI-driven platform for the rational design of molecular glue therapeutics.

Molecular glues are small molecules that induce proximity between two proteins, enabling targeted degradation or modulation of disease-driving targets that lack conventional drug-binding sites.

The platform integrates machine learning, physics-based molecular modelling, and iterative experimental validation.

Lead programmes are focused on inflammatory and neuroinflammatory diseases.